Medite Cancer Diagnostics, Inc. (MDIT)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: May 5, 2025

Medite Cancer Diagnostics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2017 FY 2016 FY 2015 FY 2014 FY 2013 2012
Period Ending
May '25 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 2012
Market Capitalization
0911245811
Upgrade
Market Cap Growth
21.66%-19.96%-55.65%-58.25%451.30%-88.68%
Upgrade
Enterprise Value
-1316286413
Upgrade
Last Close Price
0.000.300.511.153.01263.00
Upgrade
PE Ratio
-----194.82
Upgrade
PS Ratio
0.001.261.162.455.281.06
Upgrade
PB Ratio
0.001.491.342.646.884.01
Upgrade
P/TBV Ratio
-----4.01
Upgrade
EV/Sales Ratio
-1.931.752.805.781.26
Upgrade
EV/EBITDA Ratio
-----25.28
Upgrade
EV/EBIT Ratio
-----42.65
Upgrade
Debt / Equity Ratio
0.940.940.550.430.461.64
Upgrade
Debt / EBITDA Ratio
-----8.69
Upgrade
Asset Turnover
0.440.410.510.530.821.29
Upgrade
Inventory Turnover
1.682.141.631.881.951.59
Upgrade
Quick Ratio
0.200.140.200.390.330.42
Upgrade
Current Ratio
1.110.920.730.920.851.54
Upgrade
Return on Equity (ROE)
-73.70%-98.72%-25.17%-9.76%-12.65%2.15%
Upgrade
Return on Assets (ROA)
-13.68%-24.16%-5.78%-2.02%-1.84%2.37%
Upgrade
Return on Capital (ROIC)
-19.47%-34.29%-8.13%-2.94%-2.56%2.79%
Upgrade
Return on Capital Employed (ROCE)
-----7.00%
Upgrade
Earnings Yield
-63127.84%-79.25%-20.14%-3.55%-1.21%0.51%
Upgrade
FCF Yield
-61729.40%-43.09%-11.23%-2.46%-2.33%-4.74%
Upgrade
Buyback Yield / Dilution
-99.94%-23.40%-6.08%-11.47%-23.34%-
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.